Many commonly used chemotherapeutics including oxaliplatin are associated with the development of a painful chemotherapy-induced peripheral neuropathy (CIPN). This dose-limiting complication can appear long after the completion of therapy causing a significant reduction in quality-of-life and impeding cancer treatment. We recently reported that activation of the G i /G q -coupled A 3 adenosine receptor (A 3 AR) with selective A 3 AR agonists (i.e., IB-MECA) blocked the development of chemotherapy induced-neuropathic pain in models evoked by distinct agents including oxaliplatin without interfering with their anticancer activities. The mechanism(s) of action underlying these beneficial effects has yet to be explored. Our results herein demonstrate that the development of oxaliplatin-induced mechanohypersensitivity (allodynia and hyperalgesia) in rats is associated with the hyperactivation of astrocytes, but not microglial cells, increased production of pro-inflammatory and neuroexcitatory cytokines (TNF, IL-1b), and reductions in the levels of anti-inflammatory/neuroprotective cytokines (IL-10, IL-4) in the dorsal horn of the spinal cord. These events did not require lymphocytic mobilization since oxaliplatin did not induce CD45 + /CD3 + T-cell infiltration into the spinal cord. A 3 AR agonists blocked the development of neuropathic pain with beneficial effects strongly associated with the modulation of spinal neuroinflammatory processes: attenuation of astrocytic hyperactivation, inhibition of TNF and IL-1b production, and an increase in IL-10 and IL-4. These results suggest that inhibition of an astrocyte-associated neuroinflammatory response contributes to the protective actions of A 3 AR signaling and continues to support the pharmacological basis for selective A 3 AR agonists as adjuncts to chemotherapeutic agents for the management of chronic pain.
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Introduction
Oxaliplatin, a third generation platinum compound used for the treatment of metastatic colorectal cancer, is hindered by the dose-limiting development of chemotherapy-induced peripheral neuropathy (CIPN) accompanied by chronic neuropathic pain (Farquhar-Smith, 2011; Quasthoff and Hartung, 2002) . The primarily sensory symptoms occur in up to 60% of patients and commonly have a delayed manifestation that can linger for years (Velasco and Bruna, 2010; Argyriou et al., 2008) . Unfortunately, these patients suffer from both the physical symptoms and a decreased qualityof-life (Farquhar-Smith, 2011; Kannarkat et al., 2007) . Critically, according to the American Society of Clinical Oncology no agents are currently recommended to either prevent or treat CIPN (Hershman, 2014) and unfortunately, current pain drugs only offer marginal relief due to either a lack of efficacy or the risk of unacceptable side effects (Farquhar-Smith, 2011) .
The purine nucleoside adenosine generated in both intra-and extracellular spaces by almost all cell types (Zimmermann, 2000) has been shown to play an important role in many processes including pain (Chen et al., 2013; Fredholm, 2011) . In response to stress or injury, the extracellular concentration of adenosine can increase up to 1000-fold (Ballarin et al., 1991) and elicit responses in various cell types of the central nervous system including
